These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
258 related articles for article (PubMed ID: 36815984)
1. Breviscapine alleviates podocyte injury by inhibiting NF-κB/NLRP3-mediated pyroptosis in diabetic nephropathy. Sun L; Ding M; Chen F; Zhu D; Xie X PeerJ; 2023; 11():e14826. PubMed ID: 36815984 [TBL] [Abstract][Full Text] [Related]
2. Astragaloside IV Attenuates High-Glucose-Induced Impairment in Diabetic Nephropathy by Increasing Klotho Expression via the NF- He J; Cui J; Shi Y; Wang T; Xin J; Li Y; Shan X; Zhu Z; Gao Y J Diabetes Res; 2023; 2023():7423661. PubMed ID: 37261217 [TBL] [Abstract][Full Text] [Related]
3. TRIM29 promotes podocyte pyroptosis in diabetic nephropathy through the NF-kB/NLRP3 inflammasome pathway. Xu X; Qin Z; Zhang C; Mi X; Zhang C; Zhou F; Wang J; Zhang L; Hua F Cell Biol Int; 2023 Jun; 47(6):1126-1135. PubMed ID: 36841942 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of NLRP3 inflammasome ameliorates podocyte damage by suppressing lipid accumulation in diabetic nephropathy. Wu M; Yang Z; Zhang C; Shi Y; Han W; Song S; Mu L; Du C; Shi Y Metabolism; 2021 May; 118():154748. PubMed ID: 33675822 [TBL] [Abstract][Full Text] [Related]
5. Triptolide protects against podocyte injury in diabetic nephropathy by activating the Nrf2/HO-1 pathway and inhibiting the NLRP3 inflammasome pathway. Lv C; Cheng T; Zhang B; Sun K; Lu K Ren Fail; 2023 Dec; 45(1):2165103. PubMed ID: 36938748 [No Abstract] [Full Text] [Related]
6. Lysophosphatidic Acid Induces Podocyte Pyroptosis in Diabetic Nephropathy by an Increase of Egr1 Expression via Downregulation of EzH2. Kim D; Ban KY; Lee GH; Jun HS Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373116 [TBL] [Abstract][Full Text] [Related]
7. FOXM1-activated SIRT4 inhibits NF-κB signaling and NLRP3 inflammasome to alleviate kidney injury and podocyte pyroptosis in diabetic nephropathy. Xu X; Zhang L; Hua F; Zhang C; Zhang C; Mi X; Qin N; Wang J; Zhu A; Qin Z; Zhou F Exp Cell Res; 2021 Nov; 408(2):112863. PubMed ID: 34626587 [TBL] [Abstract][Full Text] [Related]
8. ManNAc protects against podocyte pyroptosis via inhibiting mitochondrial damage and ROS/NLRP3 signaling pathway in diabetic kidney injury model. Gao Y; Ma Y; Xie D; Jiang H Int Immunopharmacol; 2022 Jun; 107():108711. PubMed ID: 35338958 [TBL] [Abstract][Full Text] [Related]
9. Astragaloside IV Alleviates Podocyte Injury in Diabetic Nephropathy through Regulating IRE-1α/NF-κ B/NLRP3 Pathway. Sun DL; Guo ZY; Liu WY; Zhang L; Zhang ZY; Hu YL; Li SF; Zhang MY; Zhang G; Wang JJ; Fang JA Chin J Integr Med; 2024 Jul; ():. PubMed ID: 39039342 [TBL] [Abstract][Full Text] [Related]
10. STING deletion alleviates podocyte injury through suppressing inflammation by targeting NLRP3 in diabetic kidney disease. Yang X; Chen Z; Luo Z; Yang D; Hao Y; Hu J; Feng J; Zhu Z; Luo Q; Zhang Z; Liang W; Ding G Cell Signal; 2023 Sep; 109():110777. PubMed ID: 37329999 [TBL] [Abstract][Full Text] [Related]
11. Artificially Cultivated Wang C; Hou XX; Rui HL; Li LJ; Zhao J; Yang M; Sun LJ; Dong HR; Cheng H; Chen YP J Diabetes Res; 2018; 2018():1390418. PubMed ID: 30534570 [TBL] [Abstract][Full Text] [Related]
12. Solasonine alleviates high glucose-induced podocyte injury through increasing Nrf2-medicated inhibition of NLRP3 activation. Zhang Q; Hu Y; Hu JE; Zhang M Drug Dev Res; 2022 Nov; 83(7):1697-1706. PubMed ID: 36048966 [TBL] [Abstract][Full Text] [Related]
13. Berberine ameliorates diabetic nephropathy by inhibiting TLR4/NF-κB pathway. Zhu L; Han J; Yuan R; Xue L; Pang W Biol Res; 2018 Mar; 51(1):9. PubMed ID: 29604956 [TBL] [Abstract][Full Text] [Related]
14. Penehyclidine hydrochloride suppresses inflammation response and reduces podocyte injury in diabetic nephropathy by targeting fibrinogen-like protein 2. Tan HB; Zhao Q; Chen L Int Immunopharmacol; 2022 Jun; 107():108680. PubMed ID: 35303505 [TBL] [Abstract][Full Text] [Related]
15. Spop ameliorates diabetic nephropathy through restraining NLRP3 inflammasome. Wang B; Dai Z; Gao Q; Liu Y; Gu G; Zheng H Biochem Biophys Res Commun; 2022 Feb; 594():131-138. PubMed ID: 35081502 [TBL] [Abstract][Full Text] [Related]
16. Sarsasapogenin alleviates diabetic nephropathy through suppression of chronic inflammation by down-regulating PAR-1: In vivo and in vitro study. Tang ZZ; Zhang YM; Zheng T; Huang TT; Ma TF; Liu YW Phytomedicine; 2020 Nov; 78():153314. PubMed ID: 32882582 [TBL] [Abstract][Full Text] [Related]
17. Protective effect of ginsenoside metabolite compound K against diabetic nephropathy by inhibiting NLRP3 inflammasome activation and NF-κB/p38 signaling pathway in high-fat diet/streptozotocin-induced diabetic mice. Song W; Wei L; Du Y; Wang Y; Jiang S Int Immunopharmacol; 2018 Oct; 63():227-238. PubMed ID: 30107367 [TBL] [Abstract][Full Text] [Related]
18. Pyrroloquinoline quinone ameliorates renal fibrosis in diabetic nephropathy by inhibiting the pyroptosis pathway in C57BL/6 mice and human kidney 2 cells. Qu X; Zhai B; Liu Y; Chen Y; Xie Z; Wang Q; Wu Y; Liu Z; Chen J; Mei S; Wu J; You Z; Yu Y; Wang Y Biomed Pharmacother; 2022 Jun; 150():112998. PubMed ID: 35489281 [TBL] [Abstract][Full Text] [Related]
19. Study on the inhibitive effect of Catalpol on diabetic nephropathy. Chen J; Yang Y; Lv Z; Shu A; Du Q; Wang W; Chen Y; Xu H Life Sci; 2020 Sep; 257():118120. PubMed ID: 32693244 [TBL] [Abstract][Full Text] [Related]